The way I think about it is that pharma CI operates under conditions that are fundamentally different from CI in any other industry.
Long development timelines. From discovery to market takes 10–15 years. CI has to maintain relevance across a timeline that outlasts most business planning cycles. Your competitors may be years ahead or years behind, and the intelligence picture changes constantly.
Massive capital at risk. Development costs exceed $1 billion per approved drug. Every intelligence failure carries enormous financial consequences. A missed competitive signal can mean hundreds of millions wasted on a program that should have been terminated or redirected.
Regulatory gatekeeping. FDA, EMA, and other regulatory bodies create a unique competitive dynamic. Approval decisions are binary, public, and precedent-setting. Regulatory intelligence is not a nice-to-have — it's a competitive weapon.
Binary clinical trial outcomes. Phase III trials either meet their primary endpoints or they don't. Anticipating those outcomes — and their downstream implications — is a core CI function.
Patent cliffs and generic entry. The transition from branded exclusivity to generic competition follows predictable but complex patterns that require specialized intelligence on IP, regulatory routes, and competitive timing.
Multi-stakeholder decision-making. Unlike consumer markets, pharmaceutical purchasing involves physicians, payers, patients, hospital formulary committees, and regulators. Each has different information needs, different competitive dynamics.
These characteristics mean the general CI principles — covered in What Is Competitive Intelligence? — have to be adapted and intensified for pharma. What really is unique to competitive intelligence is human judgment and the ability to gather non-public information by talking to people. Even as data becomes ubiquitous and AI tools multiply, that combination of domain expertise and personal networks is the enduring differentiator.
One of the most consequential decisions a pharma company makes about its CI function is how it defines the scope. Companies that define competitive intelligence narrowly — as a news clipping exercise or desktop research service — build something fragile and easily disrupted. Companies that define it as the analytical process of integrating different types of data, and ensuring executives take action on that analysis, build a sustainable strategic capability.
In pharma, the CI definition encompasses:
The distinction matters because the two disciplines are frequently confused or merged. In pharma:
CI uses fewer sources and does not pay for information (except public databases and normal honoraria). It draws on a greater variety of source types: competitors, KOLs, vendors, payers, regulators — not just patients and physicians. Sources are targeted in their natural habitat: conferences, advisory boards, medical meetings, investor calls. CI does not target patients or physicians except for KOLs and investigators involved in clinical trials. And CI has fewer legal restrictions on where it can be conducted compared to market research.
Pharma CI is only valuable if it meets three standards: accuracy (reliable sources, plausible conclusions, corroborated findings), relevance (addresses actual decision-making needs), and timeliness (delivered before the decision window closes). Miss any one of those, and the intelligence fails — regardless of how comprehensive the research was.
An effective pharma CI system has to map intelligence needs across nine knowledge domains. I'll walk through each.
This is the foundation of pharmaceutical competition. What's the IP status of competitors within the class? What freedom to operate do we have? What's our patent portfolio strategy versus competitors'? What type and duration of patent protection is available, including supplementary protection certificates? What patents do competitors hold for pro-drugs, metabolites, intermediates, isomers, salts, and other physical forms? Get this wrong, and everything downstream collapses.
Beyond standard market data: What unique formulations do competitors have? How complex and expensive is their drug to synthesize compared with ours? What are the product benefits for specific patient populations? What's the competitor publication plan, and how is it aligned with regulatory timelines? How are competitors using digital and social media? What markets face generic entry risk?
The technical heart of pharma CI: How are competitors leveraging disease pathways based on mechanism of action? How does our product compare on efficacy, safety, and tolerability? What companion diagnostics are in development? What pharmacogenomics studies are competitors running? Are they planning dosage, formulation, or regimen changes to further differentiate?
Monitoring new technologies and identifying collaboration opportunities through journal literature, patent searches, and conference intelligence.
Continuous monitoring for players dropping out, new entrants from unexpected directions, disruptive technologies from small firms. The company has to think expansively about who might compete — not just the obvious names. Conference intelligence is particularly productive here: watching who presents what, who's recruiting for which positions, which investigators are attached to which programs.
How competitors get their products to market. Sales force sizing and structure, advertising benchmarks, go-to-market tactics. Field force intelligence — who's detailing what, and where — can reveal a competitor's strategic priorities faster than their press releases.
Competitor R&D bottlenecks, development priorities, manufacturing innovations. Reading competitors' publications and talking with their scientists at conferences reveals where they're stuck and where they're investing.
Pediatric exclusivity, combination therapy exclusivity, Regulatory Data Protection, bio-equivalence requirements, generic regulatory routes, submission and approval timelines. In a business where regulatory strategy can make or break a product, this intelligence is non-negotiable.
The VC landscape, M&A candidates, competitor staffing strategies, salary benchmarks. Job advertisements alone can reveal where a competitor is building capability — a hiring surge in market access or medical affairs tells you something about their timeline.
AI is enabling a new type of intelligence — systematic profiling of healthcare professionals using public data. Sunshine Act payments, publication histories, clinical trial involvement, social media commentary. The shift is headquarters giving intelligence to the field to enable better conversations. One company we worked with gave us a list of 6,000 target physicians and needed to figure out who to prioritize. That kind of analysis used to take months. With AI, it takes days.
The organizational model for CI says a lot about where intelligence sits in the decision-making hierarchy. In pharma, three dominant structures exist, each with distinct tradeoffs.
A dedicated CI team with a CI Head, organized by business unit or therapeutic area. Companies like a major biotech company, a top-10 pharma company, a top-10 pharma company, and a top-10 pharma company run versions of this.
The scope can be expansive. The head of a CI Center of Excellence at a top-10 pharma company, captures it well: "We work with teams from the bench to the board." That means intelligence covering everything from early-stage molecule assessment, through clinical development strategy, to commercial launch readiness.
The advantages are scale, specialization, standardized methods, a clear career path for CI professionals, and a degree of analytical objectivity that comes from sitting outside any single brand team. The risk is creating barriers between the CI function and the rest of the organization. Centralization can become a silo if the team prioritizes analytical rigor over proximity to decision makers.
A CI professional embedded in each product team or business unit, reporting to the insights lead or BU head. a major pharma company, AbbVie, and Bayer have run this model.
The advantage is proximity — you're closer to decision makers, you understand the brand context, you can respond faster. The disadvantage is structural: without a common CI culture, there's no standardization, no best-practice sharing, and limited career progression for CI professionals. Each embedded person develops their own approach, and quality varies across the portfolio.
A single generalist insights manager combines CI with market research, business analytics, and forecasting. Companies like Shire, Celgene, and a major pharma company have used this approach.
You get the holistic brand view — the same person tracking competitive dynamics also understands the market research and the forecasting. But there's no CI champion, and the risk of becoming jack of all trades is real. CI becomes one task among many rather than a distinct strategic discipline.
The operating model matters less than two things: executive sponsorship and a competitive mindset. How do you get into the room where strategic decisions are being made? How do you present the data in a way that influences decision-making? How do you build team alignment when commercial, medical, and regulatory each see the competitive threat differently? That's where CI earns its seat at the table — or loses it.
What you deliver — and when — depends on where the asset sits in its lifecycle. The investment, the intensity, and the deliverable mix all change as a compound moves from clinical development through launch to loss of exclusivity.
Budget: 100–300K CHF | Resource: 0.1–0.3 FTE
This is the foundational layer. Deliverables include competitive pipelines and landscapes, clinical trial trackers, key event timelines, product profile comparisons, conference coverage, and secondary monitoring. The intelligence focus is broad: who else is in the space, what data is emerging, and how does the competitive picture affect development decisions.
Running beneath all of this are KITs/KIQs and the collection plan — the intelligence requirements that determine what gets tracked and why. Without that foundation, you're collecting data without direction.
Budget: 250K–1M CHF | Resource: 0.3–0.5 FTE
Everything from Phase II/III continues, but the deliverable set expands substantially: early warning systems, competitor lifecycle management intelligence, competitive simulations (war games), FMEA/CTA (competitive threat assessments), deep dives, Gx and biosimilar tracking, litigation monitoring, guidelines intelligence, and internal network coordination.
This is the most CI-intensive period. The intelligence has to be faster, more specific, and more directly connected to commercial decisions. A competitor's Phase III readout that drops on a Friday evening can shift market dynamics before your team sees it Monday morning.
Budget: 200–750K CHF | Resource: 0.2–0.4 FTE
The intelligence focus shifts to competitor lifecycle management and Gx/biosimilar CI — manufacturing intelligence, regulatory routes and strategies, vertical structures, legal basis for generic entry, and marketing authorization tracking. The competitive landscape goes from a handful of branded competitors to potentially dozens of generic entrants across a multi-tiered value chain.
For how these deliverables evolve across each stage gate and decision point, see How CI Evolves From Drug Discovery to Commercial Launch.
The CI process in pharma follows the same cycle we developed and published in Nature Biotechnology: Intelligence requirements → Collection plan → Secondary collection → Human collection → Processing and analyzing → Final analysis → CI Review → Strategy.
The goal is not to gather copious amounts of information but to produce highly relevant analysis. A successful CI process begins and ends by understanding the company or product strategy — expressed through Key Intelligence Topics and Key Intelligence Questions.
KIQs get prioritized by what it takes to answer them. High-priority KIQs justify dedicated human source collection. Medium-priority KIQs are tracked through secondary sources with human follow-up. Low-priority KIQs get reported as information surfaces. Review KITs every six months with the Franchise Head, quarterly with the operational team, and continuously as key findings generate follow-up questions.
But here's what most people underestimate. The process is only half the challenge. The other half is ensuring insights translate into action. You can have the best tools, the best analysts, and the best processes, but if competition isn't part of how the organization thinks and makes decisions, insights will sit on a shelf. If the CEO and senior leadership aren't actively driving a competitive mindset, CI will always be treated as a support function rather than a strategic input.
The organizations getting real value from CI are embedding it into both strategic planning cycles and in-year tactical decisions — creating a continuous intelligence thread rather than producing periodic reports. That's where the real shift is happening.
For the comprehensive KIQs methodology, see Key Intelligence Questions: The Foundation of Any CI Program.
Pharma CI draws on a wide taxonomy of sources. Vendors, clinical and R&D contacts, corporate business sources, government agencies, media, non-profits, payers, pharmacies, sales representatives, and investigators all contribute different pieces of the picture.
Secondary sources provide the foundation: company websites, trade publications, scientific journals, PubMed, regulatory agency databases (FDA, EMA), ClinicalTrials.gov, SEC filings, patent databases (EPO, USPTO), LinkedIn, conference abstracts, and subscription platforms like AdisInsight and TrialTrove.
Primary (human) sources provide the competitive advantage. The reason is simple: the information is not publicly available to everyone. When you're talking with a KOL who sits on your competitor's advisory board, or a former employee who understands their clinical development strategy, you're getting intelligence that no database can provide.
With AI, the source management challenge has changed dramatically. Three years ago, we had people doing news monitoring who would spend probably about three hours per day logging into email, Google Alerts, different access feeds and different databases. All of that can now be centralized. We're now managing 3,000+ curated sources across six categories — regulatory and FDA/EMA filings, congress abstracts, investor relations, news wires and PR, clinical registries, and foreign-language press — with continuous automated monitoring and feed health checks. That kind of coverage would have been impossible manually.
But the real competitive advantage in source management is still human. That's not a technology problem. That's expertise, credibility, and relationships — and it's where the best CI teams set themselves apart.
War games — interactive workshops where participants role-play competitors to simulate future competitive environments — are among the most powerful deliverables in pharma CI. They challenge beliefs and assumptions, identify risks and opportunities, understand implications for your own strategy, and produce action plans.
When to use them: at any point in the lifecycle, but especially when the environment is changing — new data releases, new product entries, annual brand planning.
One insight from decades of running these: 50% of all your CI needs can be found within your own company — you just don't know where it is. War games surface that internal knowledge. A regulatory person shares something the commercial team never knew. A medical affairs director mentions a conversation from a congress six months ago that suddenly connects with a data readout. The cross-functional collision is as valuable as the competitive role-play.
The ocean racing analogy captures the dynamics. Teams compete with boats (brands), with core boat design (R&D) essential, but success driven by route planning (global brand team), sailing execution (local brand teams), innovation (lifecycle management), while coping with evolving rules (regulations), weather conditions (payer attitudes), and local currents (stakeholder behaviors).
The honest answer about AI in pharma CI is that you can't do it with researchers alone anymore. The volume of data — publications, clinical trial registrations, regulatory filings, congress abstracts, earnings calls, social media — has grown beyond what any human team can systematically process.
But that doesn't mean you hand everything to AI and walk away. The biggest risk is overconfidence. People start trusting the system to give them good answers and stop questioning the outputs. The problem is that AI can be confidently wrong, and it takes human judgment and domain expertise to catch it.
The organizations getting value from AI are doing four things differently. First, they're automating the monitoring layer — 24/7 coverage across 3,000+ sources, alerts in under 20 minutes, any-language support at roughly 60% lower cost. Second, they're expanding scope — we work with a small pharma company that five years ago was only tracking one or two indications. Now, because AI makes it affordable, they're tracking 40. That's not a marginal improvement; that's a completely different level of strategic awareness. Third, they're embedding AI into decision-making cycles, not treating it as a standalone tool. Fourth, they're maintaining human oversight — explainability is non-negotiable.
There's a broader shift in how intelligence reaches stakeholders. Chris The CI leader describes the vision at a top-10 pharma company: transitioning from PowerPoint decks and PDF documents to dynamic dashboards and AI-powered chatbots that can answer questions in real time. The biggest barrier, in his view, is organizational silos — different parts of the company building their own AI tools independently.
a senior strategy executive at a top-10 pharma company has taken a different but complementary approach. His Enterprise Strategy team built what they call the "a centralized intelligence system" — uploading all their intellectual property and institutional knowledge into a centralized AI system. The logic is practical: "Your best shot is your first shot." When a strategist approaches a new problem with the full weight of the organization's accumulated knowledge behind them, the first set of recommendations is dramatically stronger than it would be otherwise.
That's the compounding effect. Each cycle of knowledge-learning-agency makes the next one sharper. Adoption gets faster, outputs get better, time to quality compresses. The operating model shifts from batch processing to continuous intelligence.
But the core of pharma CI remains what it has always been: human judgment, human networks, and the ability to connect data points that no algorithm would think to link. AI gives you speed and scale. People give you judgment and influence. The companies that combine both are the ones pulling ahead.
Generics intelligence is different enough from branded pharma CI to deserve its own treatment.
The competitive landscape at loss of exclusivity shifts from a handful of branded competitors to potentially dozens of generic entrants across a complex, multi-tiered value chain. An average of 83 players per blockbuster active ingredient in the EU-15. The key objective for generic competitors is first to market — it's a necessary condition for long-term market share. CI has to identify which of those 83 players will get there.
The intelligence requirement spans the entire value chain: intermediate manufacturers, API manufacturers, contract manufacturers, dossier developers, CROs conducting bio-equivalence studies, regulatory consultants, marketing companies, and distribution channels. Each tier needs to be mapped and monitored.
The regulatory dimension is particularly detailed. Four main application types for generic market entry — Article 10.1 (abridged), Article 10.3 (hybrid), Article 10a (bibliographic), and Mixed Applications — each with specific conditions, data exclusivity calculations, and bioequivalence requirements. Standard bioequivalence demonstration requires AUCt and Cmax within the 80–125% range, narrowing to 90–111% for narrow therapeutic index drugs.
White tablet Gx intelligence and biosimilar intelligence operate on fundamentally different premises. White tablets have high player counts and excessive noise — the challenge is identifying signal. Biosimilars have fewer players but dramatically higher complexity in characterization, production, clinical requirements, and regulatory hurdles.
CI ethics are not necessarily the same around the world, across industries, within the life sciences industry, or even within the same company. That's the reality, and it makes having clear guidelines essential.
The minimum standards: never disclose client names, never misrepresent who you are, never pay for information (except public databases and normal honoraria), never disclose source names, never pressure for confidential information, always identify yourself. The CI manager's responsibility is to read corporate policies, develop CI legal and ethical guidelines, create a training program, and ensure stakeholder sign-off.
The legal landscape is particularly complex in pharma because you're operating across jurisdictions with different rules on bribery, confidentiality, data protection, and information gathering. The UK Bribery Act, Indian anti-corruption laws, Chinese bribery rules, Swiss confidentiality protections — they all differ, and ignorance isn't a defense.
AI adds new ethical questions. Data sourcing, algorithmic transparency, attribution, patient privacy — these aren't fully resolved, and governance frameworks are still evolving. At minimum, every organization using AI in CI needs human-in-the-loop requirements, explainability standards, and clear organizational policies. We lost a project once because a competitor was willing to cut corners on compliance. That tells you where the industry pressure points are.
A pharma CI analyst gathers and analyzes competitive information across clinical, commercial, regulatory, and IP domains. They define intelligence requirements with stakeholders, build and maintain collection plans, conduct primary and secondary research, produce analytical deliverables, and — critically — translate intelligence into recommendations that influence business decisions. The best analysts are not just researchers. They're strategists who understand the business context and can earn their way into the room where decisions get made.
Investment benchmarks: 100–300K CHF during Phase II/III (0.1–0.3 FTE), 250K–1M CHF during Pre-Launch and Launch (0.3–0.5 FTE), 200–750K CHF during loss of exclusivity (0.2–0.4 FTE). Budgets scale with competitive intensity and the commercial value of the asset.
Core tools include ClinicalTrials.gov, PubMed, regulatory agency databases, patent databases, subscription platforms (AdisInsight, TrialTrove), financial data sources, Google Alerts, RSS feeds, and LinkedIn. AI-powered monitoring platforms now manage thousands of sources with real-time alerting, multi-language coverage, and performance tracking. But tools are only as good as the KIQs driving them and the analysts interpreting the outputs.
At the pre-clinical stage — before Phase I. Even at the earliest point, understanding who else is in the therapeutic space, what mechanisms they're pursuing, and whether the competitive landscape supports continued investment shapes the decisions that follow. CI intensity then escalates through Phase II/III, peaks at pre-launch and launch, and continues through loss of exclusivity.
AI automates monitoring, source screening, and initial summarization — tasks that consumed hours daily. It enables coverage of 3,000+ sources across languages, delivers alerts in under 20 minutes, and reduces cost by roughly 60%. But the real impact is in how CI is consumed. The shift from static PowerPoint decks to dynamic dashboards and AI-powered knowledge systems means stakeholders can access intelligence when they need it, in the format they need it. What really is unique to competitive intelligence — human judgment and non-public information through relationships — stays human.
Gx intelligence is a specialized CI discipline covering the competitive dynamics, value chain, regulatory strategy, and market structure of generic drug entry. It's portfolio-driven rather than product-driven, involves tracking a high number of competitors (averaging 83 per blockbuster in the EU-15), and requires intelligence across the entire value chain — from API manufacturing to marketing authorization. The primary competitive objective is first-to-market, making intelligence timing critical.